Mette Vadstrup, Tobias Bomholt, Kirsten Nørgaard, Ajenthen G. Ranjan, Marianne Rix, Thomas Almdal, Therese Adrian, Bo Feldt-Rasmussen & Mads Hornum
Ugeskr Læger 2019;181:V03200166
Studies indicate, that the glycated haemoglobin (HbA1c) level underestimates the mean blood glucose level in patients with Type 1- and Type 2 diabetes on haemodialysis. In patients receiving peritoneal dialysis the validity of HbA1c level is undetermined. Continuous glucose monitoring (CGM) could be an option for patients with diabetes receiving dialysis to assess the mean blood glucose level independently of the HbA1c level. In addition, CGM makes it possible to investigate periodic hypo- and hyperglycaemia and glucose variability. The evidence for the use of CGM in the dialysis population is limited but could represent an improved approach to glycaemic control.